| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/10/2010 | US20100145441 Therapeutic agents for angiogenesis-related diseases comprising chondromodulin-i as active ingredient |
| 06/10/2010 | US20100145180 Apparatus for physical measurements of the eye |
| 06/10/2010 | US20100145026 Antibody for ADCC And Inducing Cytokine Production |
| 06/10/2010 | US20100144868 Novel Neuroprotective Compounds and Uses Thereof |
| 06/10/2010 | US20100144862 Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome |
| 06/10/2010 | US20100144860 Transglutaminase Inhibitor Comprising EGCG And A Method For Producing Thereof |
| 06/10/2010 | US20100144856 Prenylfavanone compounds and uses thereof |
| 06/10/2010 | US20100144854 Use of rhodamine 6g as a medicinal agent for treating malignant neoplasms and amiloidoses |
| 06/10/2010 | US20100144851 RNA Interference Mediated Inhibition of Platelet-Derived Endothelial Cell Growth Factor (ECGF1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 06/10/2010 | US20100144850 Methods for Differentiating Pancreatic Cancer from Normal Pancreatic Function and/or Chronic Pancreatitis |
| 06/10/2010 | US20100144849 METHOD FOR INHIBITING SIGNALING MEDIATED BY ErbB2, SIGNALING INHIBITOR TO BE USED THEREFOR AND USE THEREOF |
| 06/10/2010 | US20100144848 Dna controlled assembly of lipid membranes |
| 06/10/2010 | US20100144847 Fusion polypeptide suitable as a cytotoxin |
| 06/10/2010 | US20100144846 Oligoribonucleotides and uses thereof |
| 06/10/2010 | US20100144845 Oligonucleotide systems for targeted intracellular delivery |
| 06/10/2010 | US20100144844 RNAi-MEDIATED INHIBITION OF H1F1A FOR TREATMENT OF OCULAR ANGIOGENESIS |
| 06/10/2010 | US20100144842 RNA Interference Mediated Inhibition of NOGO and NOGO Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 06/10/2010 | US20100144841 Control of nk cell function and survival by modulation of ship activity |
| 06/10/2010 | US20100144839 Anti-cancer oligodeoxynucleotides |
| 06/10/2010 | US20100144838 Methods for Identifying Modulators of Pyrimidine Tract Binding Protein |
| 06/10/2010 | US20100144837 Diagnosis and treatment of malignant neoplasms |
| 06/10/2010 | US20100144836 Methods for Detecting Epigenetic Modifications |
| 06/10/2010 | US20100144832 Prostate Cancer-Specific Alternations in ERG Gene Expression and Detection and Treatment Methods Based on Those Alterations |
| 06/10/2010 | US20100144827 Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof |
| 06/10/2010 | US20100144826 Salinosporamides and Methods for Use Thereof |
| 06/10/2010 | US20100144823 Novel indole derivatives as selective androgen receptor modulators (sarms) |
| 06/10/2010 | US20100144822 Use of Inhibitors of the Degradation of P27, in Particular Argyrin and Derivatives Thereof, for the Treatment of Proliferative Diseases |
| 06/10/2010 | US20100144820 Therapeutic hpph dosage for pdt |
| 06/10/2010 | US20100144805 Regulation of protein synthesis |
| 06/10/2010 | US20100144783 Kinase inhibitors with improved cyp safety profile |
| 06/10/2010 | US20100144782 Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics |
| 06/10/2010 | US20100144779 Marine Alkalod Makaluvamines and Derivatives Thereof |
| 06/10/2010 | US20100144775 Heterocyclic Cyclopamine Analogs and Methods of Use Thereof |
| 06/10/2010 | US20100144770 Pyrimidinones as Casein Kinase II (CK2) Modulators |
| 06/10/2010 | US20100144768 Kinase inhibitor compounds |
| 06/10/2010 | US20100144764 Pyrimidinedione derivatives and methods of use thereof |
| 06/10/2010 | US20100144763 Pharmaceutical composition for inhibiting topoisomerase I and method for exploiting drug |
| 06/10/2010 | US20100144757 Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics |
| 06/10/2010 | US20100144756 Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| 06/10/2010 | US20100144751 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| 06/10/2010 | US20100144750 Use of N-Phenyl-2-Pyrimidineamine Derivatives Against Mast Cell-Based Diseases Like Allergic Disorders |
| 06/10/2010 | US20100144749 Treatment of cancers with acquired resistance to kit inhibitors |
| 06/10/2010 | US20100144745 Pyrrolopyrazinyl Urea Kinase Inhibitors |
| 06/10/2010 | US20100144743 Compositions and methods for inhibition of tyrosine kinases |
| 06/10/2010 | US20100144739 Heterocyclic inhibitors of c-met and uses thereof |
| 06/10/2010 | US20100144732 Pyrimidine kinase inhibitors |
| 06/10/2010 | US20100144730 Pyridinonyl pdk1 inhibitors |
| 06/10/2010 | US20100144721 Inhibitors of c-met and uses thereof |
| 06/10/2010 | US20100144720 Inhibitors of human tumor-expressed ccxckr2 |
| 06/10/2010 | US20100144718 Treatment of diseases modulated by a h4 receptor agonist |
| 06/10/2010 | US20100144708 Heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same for treatment of cancer |
| 06/10/2010 | US20100144707 Pharmacokinetically improved compounds |
| 06/10/2010 | US20100144706 Compounds |
| 06/10/2010 | US20100144688 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids |
| 06/10/2010 | US20100144680 Pharmaceutical compositions useful for preventing and treating oncological diseases |
| 06/10/2010 | US20100144678 Compositions and methods for treating bone cancer |
| 06/10/2010 | US20100144676 Oleyl phosphocholine |
| 06/10/2010 | US20100144671 Compositions and Methods for Cancer Treatment |
| 06/10/2010 | US20100144665 Treatment of statin side effects |
| 06/10/2010 | US20100144663 2, 6-Dinitrogen-Containing Substituted Purine Derivatives, The Preparation And Uses Thereof |
| 06/10/2010 | US20100144660 Use of n,n-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer thereapy |
| 06/10/2010 | US20100144659 Targeting agent for cancer cell or cancer-associated fibroblast |
| 06/10/2010 | US20100144653 Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof |
| 06/10/2010 | US20100144652 Composition comprising a glycolytic inhibitor and a ring system comprising a sulphamate group for the treatment of cancer |
| 06/10/2010 | US20100144649 Compounds for enzyme inhibition |
| 06/10/2010 | US20100144648 Compounds for enzyme inhibition |
| 06/10/2010 | US20100144647 Dual Acting Prodrugs |
| 06/10/2010 | US20100144641 Compositions Having Antiangiogenic Activity and Uses Thereof |
| 06/10/2010 | US20100144637 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer |
| 06/10/2010 | US20100144636 Peptides derived from ras-p21 and uses therefor |
| 06/10/2010 | US20100144632 Administering a polypeptide having at least one of anti-angiogenic, tumor-suppressive, or anti-migratory activity, but does not have stimulation of cell proliferation activity |
| 06/10/2010 | US20100144628 Hepatopoietin and use thereof |
| 06/10/2010 | US20100144624 Process for the preparation of compositions of at1 receptor antagonist and angiotensin-(1-7) |
| 06/10/2010 | US20100144602 Methods of Inhibiting Metastatic Cancer by Administration of Streptolysin O |
| 06/10/2010 | US20100144600 Osteoprotegerin variant proteins |
| 06/10/2010 | US20100144599 Vegf pathway blockade |
| 06/10/2010 | US20100144589 Methods of predicting cancer lethality using replikin counts |
| 06/10/2010 | US20100144039 Pluripotency determining factors and uses thereof |
| 06/10/2010 | US20100143511 Scutellaria barbata extract for the treatment of cancer |
| 06/10/2010 | US20100143508 Limonene and yucca medical compound for treating human diseases and conditions |
| 06/10/2010 | US20100143500 Methods and Compositions for Inhibiting GSK-3 In Glial Cell Related Disorders |
| 06/10/2010 | US20100143459 Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| 06/10/2010 | US20100143457 Extended soluble PH20 polypeptides and uses thereof |
| 06/10/2010 | US20100143456 Model membrane systems |
| 06/10/2010 | US20100143453 Anti-inflammatory compounds containing compositions for treatment of cancer |
| 06/10/2010 | US20100143442 Growth factor complexes and modulation of cell migration and growth |
| 06/10/2010 | US20100143441 Nortriptyline compounds for promoting bone growth |
| 06/10/2010 | US20100143386 FGFR4 Promotes Cancer Cell Resistance in Response to Chemotherapeutic Drugs |
| 06/10/2010 | US20100143384 NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 06/10/2010 | US20100143371 Intrabodies |
| 06/10/2010 | US20100143370 Set of means for treating a malignant pathology, an autoimmune disease or an infectious disease |
| 06/10/2010 | US20100143368 Human Antibodies That Bind Cd22 And Uses Thereof |
| 06/10/2010 | US20100143367 Novel anti-cd98 antibody |
| 06/10/2010 | US20100143366 Antitumor agent |
| 06/10/2010 | US20100143363 Cd161 ligand, pilar, for modulating activation and proliferation of t cells |
| 06/10/2010 | US20100143360 Human vascular endothelial growth factor 2 |
| 06/10/2010 | US20100143359 Expression of foxp3 by cancer cells |
| 06/10/2010 | US20100143358 Use of Antibody Conjugates |
| 06/10/2010 | US20100143356 Therapeutic and diagnostic anti-hsp70 antibodies |
| 06/10/2010 | US20100143354 Triazine dna modifiers |